SLN Silence Therapeutics plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1479615
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-98.2%
TTM net income YoY20.3%
TTM EPS YoY22.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin95.0%
Operating margin-12,343.6%
Net margin-11,276.5%
FCF margin-9,681.6%
EBITDA margin-12,279.2%
Returns
ROE-35.6%
ROA-24.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.6%
Debt / equity0.00x
Current ratio23.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $422,000 | $34,000 | $159,000 | $224,000 | $142,000 | $25.30M |
| Cost of revenue | $0 | $0 | $11,000 | $12,000 | $64,000 | $85,000 | $54,000 | $2.04M |
| Gross profit | $0 | $0 | $411,000 | $22,000 | $95,000 | $139,000 | $88,000 | $23.27M |
| R&D expense | $9.30M | $9.15M | $9.12M | $8.75M | $20.54M | $17.65M | $20.81M | $22.08M |
| SG&A expense | $4.92M | $4.72M | $7.03M | $3.73M | $5.79M | $5.13M | $7.68M | $5.54M |
| Operating income | -$14.22M | -$13.87M | -$15.74M | -$12.46M | -$26.24M | -$23.96M | -$28.41M | -$4.35M |
| Pretax income | -$12.43M | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.34M | -$28.53M | $12.63M |
| Income tax | $0 | $1,000 | $0 | $0 | $1,000 | $10,000 | $0 | $324,000 |
| Net income | -$12.43M | -$12.27M | -$14.96M | -$11.77M | -$20.96M | -$27.35M | -$28.53M | $12.30M |
| EBITDA | -$14.15M | -$13.79M | -$15.66M | -$12.38M | -$26.16M | -$23.88M | -$28.34M | -$4.28M |
| EPS (basic) | -0.08 | -0.09 | -0.11 | — | -0.15 | -0.19 | -0.20 | — |
| EPS (diluted) | -0.08 | -0.09 | -0.11 | — | -0.15 | -0.19 | -0.20 | — |
| Weighted avg. shares (diluted) | 165.60M | 141.71M | 141.70M | — | 141.70M | 141.70M | 141.68M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $247.66M | $72.05M | $5.66M | $11.28M | $82.03M | $41.74M | $64.89M | $121.33M |
| Short-term investments | $0 | $0 | $64.42M | $73.84M | $20.16M | $72.42M | $71.65M | $26.00M |
| Receivables | — | — | $0 | $0 | $28,000 | $85,000 | $41,000 | $972,000 |
| Current assets | $269.58M | $94.28M | $102.85M | $118.66M | $133.63M | $148.55M | $169.79M | $187.37M |
| PP&E, net | $1.22M | $1.32M | $1.40M | $1.58M | $1.66M | $1.77M | $1.69M | $1.82M |
| Goodwill | $10.25M | $10.32M | $10.36M | $10.62M | $10.62M | $10.62M | $10.62M | $9.39M |
| Intangibles | — | — | — | $288,000 | — | — | — | $312,000 |
| Total assets | $281.50M | $106.41M | $115.12M | $131.44M | $146.79M | $165.23M | $185.30M | $202.63M |
| Current liabilities | $11.26M | $12.71M | $10.46M | $13.61M | $17.38M | $14.77M | $19.26M | $16.82M |
| Total liabilities | $66.48M | $67.94M | $65.72M | $69.14M | $72.73M | $71.08M | $72.56M | $68.61M |
| Shareholders' equity | $215.02M | $38.47M | $49.40M | $62.30M | $74.06M | $94.16M | $112.74M | $134.02M |
| Shares outstanding | 186.61M | 141.74M | 141.70M | 141.70M | 141.70M | 141.70M | 141.69M | 141.67M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.78M | $1.52M | -$15.60M | -$17.29M | -$10.89M | -$21.78M | -$12.31M | -$27.48M |
| Capital expenditure | $0 | $0 | $0 | $0 | $3,000 | $48,000 | $4,000 | $62,000 |
| Free cash flow | -$12.78M | $1.52M | -$15.60M | -$17.29M | -$10.89M | -$21.83M | -$12.31M | -$27.54M |
| Investing cash flow | $0 | $64.94M | $10.00M | -$53.34M | $51.29M | -$1.56M | -$44.38M | $66.12M |
| Financing cash flow | $188.33M | $2,000 | $0 | $0 | $0 | $1,000 | $14,000 | -$98,000 |
| Depreciation & amortization | $72,000 | $73,000 | $72,000 | $77,000 | $81,000 | $81,000 | $73,000 | $76,000 |
| Stock-based compensation | $777,000 | $1.31M | $2.45M | -$86,000 | $2.54M | $2.08M | $3.54M | $3.98M |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.